IDEAYA Biosciences Future Growth
Future criteria checks 2/6
IDEAYA Biosciences se prevé un crecimiento anual de los beneficios y los ingresos de 21.3% y 50.6% respectivamente. Se prevé que el BPA sea de grow en 32.7% al año. Se prevé que la rentabilidad de los fondos propios sea de -41.4% en 3 años.
Key information
41.5%
Earnings growth rate
43.5%
EPS growth rate
Biotechs earnings growth | 20.8% |
Revenue growth rate | 52.1% |
Future return on equity | -30.1% |
Analyst coverage | Good |
Last updated | 20 Mar 2024 |
Recent future growth updates
Recent updates
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
May 16We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12IDEAYA Biosciences EPS beats by $0.01, misses on revenue
May 10If You Had Bought IDEAYA Biosciences (NASDAQ:IDYA) Shares A Year Ago You'd Have Earned 181% Returns
Mar 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 87 | -163 | -206 | -202 | 7 |
12/31/2025 | 98 | -126 | -181 | -178 | 11 |
12/31/2024 | 19 | -165 | -147 | -145 | 11 |
12/31/2023 | 23 | -113 | -118 | -115 | N/A |
9/30/2023 | 23 | -103 | -116 | -115 | N/A |
6/30/2023 | 45 | -74 | -111 | -109 | N/A |
3/31/2023 | 47 | -68 | -98 | -95 | N/A |
12/31/2022 | 51 | -59 | -91 | -87 | N/A |
9/30/2022 | 50 | -53 | -85 | -80 | N/A |
6/30/2022 | 29 | -66 | -72 | -69 | N/A |
3/31/2022 | 32 | -55 | -64 | -62 | N/A |
12/31/2021 | 28 | -50 | -58 | -56 | N/A |
9/30/2021 | 36 | -37 | -53 | -51 | N/A |
6/30/2021 | 36 | -30 | 50 | 52 | N/A |
3/31/2021 | 27 | -31 | 50 | 51 | N/A |
12/31/2020 | 20 | -34 | 55 | 55 | N/A |
9/30/2020 | 9 | -40 | 58 | 58 | N/A |
6/30/2020 | N/A | -46 | -43 | -42 | N/A |
3/31/2020 | N/A | -44 | -40 | -39 | N/A |
12/31/2019 | N/A | -42 | -41 | -39 | N/A |
9/30/2019 | N/A | -40 | -40 | -38 | N/A |
6/30/2019 | N/A | -42 | -39 | -36 | N/A |
3/31/2019 | N/A | -38 | -34 | -32 | N/A |
12/31/2018 | N/A | -34 | -29 | -28 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: IDYA se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios frente mercado: IDYA se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: IDYA se prevé que siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: IDYASe prevé que los ingresos de la empresa (51.8% al año) crezcan más deprisa que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: IDYASe prevé que los ingresos de la empresa (51.8% al año) crezcan más deprisa que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): IDYA se prevé que no sea rentable en 3 años.